U.K. demands all SSRI data

Put your cards on the table, ladies and gentlemen. A U.K. minister is calling on drug companies to hand over all their data on antidepressants to the National Institute for Health and Clinical Excellence. NICE, you'll recall, is reviewing its guidelines for the use of SSRI drugs, aiming to issue new treatment advice this fall. Failing to hand over that data "would leave the inevitable impression they had something to hide," the minister said. In the past, another official said, the government has been unable to get access to unpublished trials.

The request comes on the heels of last week's study showing that SSRIs were effective only in the most severely depressed patients. Despite the U.K.'s official position that drugs shouldn't be the first line of defense against depression, they're among Britain's most prescribed meds with more than 31 million scrips in 2006.

- read the report from the Guardian

Related Articles:
Study: Antidepressants useless for most. Report
Antidepressants--Top 10 Warnings and Recalls of 2007. Report
Positive data more likely to find its way to public. Report
U.K. ratchets up antidepressant warnings. Report
Suicide stats fuel debate over SSRI drugs. Report

Free Webinar

What could you do with real-time supply chain information at your fingertips?

Interested in complete supply chain real-time data visibility? Unlock productivity with digital workflows, manage plants inventory with real-time supply chain information and enable faster decision-making with data visualization with pci | bridge. Register today!

Suggested Articles

Incyte and Novartis' Jakafi is eying a nod in chronic graft vs. host disease—and it may just have the data to get it done.

With a slate of vaccine authorizations on the horizon, vaccine execs from a trio of leading shot makers are looking at distribution hurdles ahead.

News of an FDA plant inspection for a Macrogenics drug boosted investor confidence in BMS' ability to meet its year-end deadline for liso-cel.